amifostine anhydrous has been researched along with razoxane in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, C | 1 |
| Trotti, A | 1 |
| Phillips, KA; Tannock, IF | 1 |
| Lewis, C; Links, M | 1 |
| Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP | 1 |
| Chadwick, DP; Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Hensley, ML; Meropol, NJ; Schuchter, LM; Winer, EP | 1 |
| Grdina, DJ; Kataoka, Y; Murley, JS | 1 |
| Antoniou, J; Chalifour, LE; Ciobanu, I; Demers, CN; Héon, S; Mwale, F; Servant, N | 1 |
| Hogle, WP | 1 |
| Bjelogrlic, SK; Jokanovic, M; Jovic, V; Radic, J; Radulovic, S | 1 |
| Cohen, GI; Emami, B; Gradishar, WJ; Green, DM; Hagerty, KL; Hensley, ML; Kewalramani, T; Meropol, NJ; Mitchell, RB; Schuchter, LM; Thigpen, JT; Trotti, A; von Hoff, D; Wasserman, TH | 1 |
6 review(s) available for amifostine anhydrous and razoxane
| Article | Year |
|---|---|
A review of the use of chemoprotectants in cancer chemotherapy.
Topics: Adrenocorticotropic Hormone; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Humans; Mesna; Neoplasms; Peptide Fragments; Razoxane | 1994 |
Toxicity antagonists in cancer therapy.
Topics: Amifostine; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Growth Substances; Humans; Mesna; Neoplasms; Palliative Care; Radiotherapy; Razoxane; Superoxide Dismutase | 1997 |
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Topics: Amifostine; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Leukopoiesis; Randomized Controlled Trials as Topic; Razoxane; Research Design; Thrombocytopenia | 1998 |
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Topics: Adrenocorticotropic Hormone; Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Female; Glutathione; Humans; Mesna; Peptide Fragments; Protective Agents; Radiation-Protective Agents; Razoxane | 1999 |
Radioprotectants: current status and new directions.
Topics: Acrolein; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Heart; Humans; Mesna; Mutagenesis; Oxazines; Radiation-Protective Agents; Radiotherapy; Razoxane | 2002 |
Cytoprotective agents used in the treatment of patients with cancer.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Fibroblast Growth Factors; Glutamine; Humans; Mesna; Neoplasms; Razoxane | 2007 |
6 other study(ies) available for amifostine anhydrous and razoxane
| Article | Year |
|---|---|
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 1999 |
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Doxorubicin; Heart Diseases; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Radiation-Protective Agents; Rats; Rats, Inbred SHR; Razoxane | 2000 |
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Topics: Amifostine; Antineoplastic Agents; Chelating Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 2002 |
Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Bone Density; Bone Resorption; Cardiovascular Agents; Doxorubicin; Drug Therapy, Combination; Female; Femur; Lumbar Vertebrae; Radiation-Protective Agents; Rats; Razoxane; Tomography, X-Ray Computed | 2005 |
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Creatine Kinase; Doxorubicin; Female; Hydroxybutyrate Dehydrogenase; Mice; Mice, Inbred BALB C; Myocardium; Radiation-Protective Agents; Razoxane; Time Factors | 2007 |
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Topics: Amifostine; Antineoplastic Agents; Fibroblast Growth Factor 7; Humans; Mesna; Neoplasms; Practice Guidelines as Topic; Radiation-Protective Agents; Razoxane | 2009 |